Utilisation thérapeutique de la N-acétylcystéine au cours des agressions pulmonaires aiguës [Therapeutic use of N-acetylcysteine in acute lung diseases]

Détails

ID Serval
serval:BIB_12519
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Utilisation thérapeutique de la N-acétylcystéine au cours des agressions pulmonaires aiguës [Therapeutic use of N-acetylcysteine in acute lung diseases]
Périodique
Revue des Maladies Respiratoires
Auteur(s)
Domenighetti G., Quattropani C., Schaller M.D.
ISSN
0761-8425
Statut éditorial
Publié
Date de publication
1999
Volume
16
Numéro
1
Pages
29-37
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Résumé
Oxidants play a key role in disease processes, particularly in the detrimental mechanisms leading to tissue damage in certain forms of acute lung injury. A number of mediators contribute to the pathologic response in ARDS, SIRS or hyperoxia-induced pulmonary damage. One of the most important detrimental factors is the generation and activation of highly reactive oxygen species which are leading factors implicated in the process of tissue damage. N-acetylcysteine (NAC) is a free radical scavenger and might access the endothelial cell thus increasing intracellular glutathione (GSH) stores. Different studies have demonstrated that NAC might be a promising compound either for the prevention or the treatment of acute lung damages such as ARDS. However, the true beneficial effect so far reported in several clinical and experimental studies contrasts with some contradictory and intriguing aspects, probably because the significance of a direct in vivo antioxidative effect of this compound remains to be established in humans. Thus, the mode of action of NAC may not be the same in different pathologies and clinical situations. More research into the mechanisms of action of this unique xenobiotic substance may offer a clue for elucidating these controversies.
Mots-clé
Acetylcysteine/therapeutic use, Acute Disease, Free Radical Scavengers/therapeutic use, Humans, Lung Diseases/drug therapy, Lung Diseases/metabolism, Reactive Oxygen Species/metabolism
Pubmed
Web of science
Création de la notice
19/11/2007 13:03
Dernière modification de la notice
20/08/2019 13:40
Données d'usage